Chronic obstructive pulmonary disease (COPD) is associated with high morbidity and mortality.
and physician perception of the impact of COPD symptoms on patients' lives is not always in concordance. Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA) has the potential to treat the symptoms of COPD in addition to improving lung function. This review therefore examines the burden of symptoms experienced throughout the day by patients with COPD and the evidence for combined LAMA/LABA treatment in terms of symptom management. As patients with COPD experience varying symptoms throughout the course of their disease, the role of tailoring treatment to the individual needs of the patient is also examined. We conclude that the symptoms of COPD are troublesome, variable, can occur during all parts of the 24-h day, and have a substantial impact on patients' health status and quality of life. In order to provide effective, patient-orientated care, patients with COPD should be evaluated on the basis of lung
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is predicted to be the fourth leading cause of morbidity and mortality around the world by 2030, and confers an increasing socioeconomic burden [1] . The World Health Organisation estimates that, globally, 64 million people had moderate to severe COPD in 2004 [2] , although the total burden of COPD is thought to be underestimated due to diagnosis usually only occurring when the disease is clinically apparent and moderately advanced [3] . The rise in morbidity and mortality from COPD over the next two decades is expected to be most dramatic in Asia and Africa, due in part to the progressive increase in the prevalence of smoking in these regions [2, 4] .
COPD is characterized by expiratory airflow obstruction, reduced elastic recoil, and reduced parenchymal tethering [5] . Reduced elastic recoil leads to hyperinflation of the lungs, which impairs chest wall and diaphragm mechanics, making breathing more difficult and increasing dyspnea. As well as dyspnea, patients with COPD experience a range of symptoms, both respiratory and systemic; these symptoms and their severity can be highly variable [5] .
There are currently several treatment options/actions for patients with COPD that can help to reduce and/or manage their symptoms, including pharmacologic therapies, pulmonary rehabilitation, and smoking cessation, all of which can also improve bronchodilation, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance [5] . However, many patients still suffer from regular symptoms that affect their daily lives and lead to increased morbidity. Therefore, selecting the right therapies and optimizing treatment to reduce airway obstruction and improve symptoms is key in improving quality of life for each patient with COPD.
This review examines the burden of symptoms experienced throughout the day by patients with COPD, the evidence for combined long-acting muscarinic antagonist and long-acting beta agonist (LAMA/LABA) treatment in terms of symptom management, and the role of tailoring treatment to the specific, individual needs of the patient.
Compliance with Ethics Guidelines
This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
DAILY SYMPTOM BURDEN OF COPD
Patients with COPD experience a range of symptoms that can vary greatly in severity. Symptoms can be respiratory-related, such as breathlessness, phlegm, cough, wheezing, and chest-tightness, as well as less specific symptoms relating to comorbidity, such as depression, anxiety, general fatigue, despondency, and sleeping difficulties [6] . Importantly, the majority of patients with COPD frequently continue to experience symptoms despite receiving treatment [6, 7] .
COPD symptoms can vary in frequency, severity, and type throughout the 24-h period, often depending on the age of the patient and the severity of their disease, with morning and nighttime symptoms reported as being particularly troublesome [6, 8, 9] . When patients do experience variability or worsening of their symptoms, many do not know how to self-manage this therapeutically, and a large proportion simply continue to use their medication in the same way [6] . Table 1 provides a summary of studies of symptom variability in patients with COPD.
24-Hour Symptom Profile
COPD symptoms and variation in symptoms over a 24-h day were investigated in the ASSESS observational study, which explored the relationship between the 24-h symptom profile and patient-reported outcomes (PROs), using a novel, 33-item questionnaire developed by the sponsor of the study [7] . The study evaluated the prevalence and severity of symptoms over three periods: in the early morning, during the daytime, and at night [7] .
Severity of airflow obstruction, health status, anxiety, depression, sleep quality, and physical activity were also evaluated to gauge the impact of symptoms. Over 90% of patients experienced COPD symptoms during at least one period of the 24-h day, and 57% of patients reported experiencing symptoms during all three periods. Stratification by disease severity revealed that even among patients with mild COPD, over 80% experienced symptoms during at least one part of the 24-h day [7] .
In ASSESS, a significant relationship was seen between severity of disease and symptoms during the early morning and the daytime, with a higher percentage of patients with severe or very severe COPD experiencing symptoms in the morning and during the day versus those with mild or moderate disease [7] . However, the proportion of patients with nighttime symptoms was similar in patients with mild, moderate, severe, and very severe disease [7, 10] .
Nearly two-thirds of patients experienced nighttime symptoms, regardless of the severity of the disease (Fig. 1a) (Fig. 1b) .
A comparison between symptoms and COPD Assessment Test (CAT) scores in patients with COPD from ASSESS showed that patients with symptoms throughout the whole 24-h day had the worst health status versus those with no symptoms or with symptoms only in one part of the day [7] .
The difference in CAT scores between patients with symptoms in all three parts of the 24-h day compared with patients without symptoms surpassed two units, the proposed estimate for a minimal clinically important difference (MCID) [7, 11] . In addition, both anxiety and depression levels were highest in patients who had symptoms in all three parts of the 24-h day and lowest in patients with no symptoms, or symptoms during only one part of the day [7] .
Morning Symptoms
Symptoms of COPD experienced in the morning are known to impact on the ability of patients to carry out daily activities, such as walking up and down stairs, washing, and getting dressed [8] , with a potential knock-on effect on the time of taking first COPD medications: one study showed that 35% of patients took their medication either whilst still in bed or immediately after getting up to relieve their COPD symptoms [8] . Patients with morning symptoms have also been shown to have higher CAT scores and lower EuroQol five dimensions questionnaire scores than those without morning symptoms, indicating a more serious impact on quality of life [12, 13] ; these patients are also at increased risk of experiencing exacerbations [13] .
Nighttime Symptoms
Symptoms of COPD experienced during the night can contribute to sleep disturbance, including difficulty falling asleep, staying asleep, and waking feeling tired, with symptoms affecting patients regardless of COPD severity [10] . In the ASSESS study, one or more symptoms was associated with a greater sleep impairment score at all three points during the 24-h day [7] . Such impairment or disruption of sleep is associated with reduced quality of life, as indicated by the Pittsburgh Sleep Quality Index score which is a significant predictor of disease-specific quality of life (as assessed using the St George's Respiratory Questionnaire [SGRQ]) [14] . It is worth noting, however, that, in some cases, sleep disturbance could also be attributed to other causes, such as a side effect of medication for heart failure or prostate hypertrophy [15, 16] .
In terms of predicted outcomes for patients with COPD, it has been reported that sleep disturbances among patients with COPD are predictive of poorer survival and increased rates of exacerbations and hospital admissions [17] [18] [19] . It has also been documented that the level of dyspnea correlates significantly to the 5-year survival rate of patients, and was more discriminating than percentage of predicted forced expiratory volume in 1 s (FEV 1 ) in predicting 5-year survival, suggesting that consideration of symptoms of breathlessness alongside airway obstruction may provide a better prognostic indicator of COPD mortality [18, 20] .
Patient and Physician Perceptions of COPD Symptoms
While a substantial body of evidence demonstrates the importance and impact of symptoms to patients, patient and physician perceptions of this impact may not always correspond. Overall, patients appear to underestimate their morbidity, and are possibly undertreated as a result [21] . Based on an objective breathlessness scale, in patients classified as too breathless to leave the house, a third described their condition as mild to moderate [21] . In another study, while both physicians and their patients identified breathlessness, fatigue, and coughing as the main symptoms of COPD that had most effect on patients' lives [22] , within the other symptom categories, such as expectoration, dry mouth, despondency, wheezing, sleeping difficulties, and chest pain, there were varying perceptions (in terms of rank) of the impact of these symptoms [22] . There was a greater degree of physician-patient concordance in patients with more severe COPD. Another study observed good concordance between the frequency of nighttime symptoms reported by patients and physicians, but also found that physicians significantly underestimated the impact of COPD symptoms on patients' lives [10] .
As current treatment options still lack control over symptoms, there remains a need for additional therapies. The exploration of treatment options that target both airway obstruction and COPD symptoms throughout the 24-h day may therefore provide patients with relief from the substantial impact that these symptoms can have on their health status. ) is a PRO designed to assess the effect of treatment on the severity of symptoms (breathlessness, cough and sputum, and chest pains) in patients with COPD in clinical trials [47] [48] [49] . The E-RS has several advantages over other COPD-specific health status questionnaires, including use of daily scores to reduce recall bias, capture of daily variability in symptoms, and simultaneous assessment of exacerbation data and respiratory symptoms [47] . In two studies, aclidinium/formoterol produced significantly greater improvements in E-RS total score versus both placebo and the monotherapies [28, 39] .
THE UTILITY OF DUAL BRONCHODILATION IN COPD

Dual Bronchodilator Therapy and Nighttime and Morning Symptoms
Although nighttime symptoms are known to negatively impact on health status, sleep disturbances, and healthcare resource utilization, current monotherapies may not adequately control these symptoms. Those patients who are most suited to treatment with dual bronchodilator therapy need to be identified and decisions made on whether treatment should be escalated and which drugs to use. In the case of a patient newly diagnosed with COPD, it would be appropriate to prescribe either a LAMA or a LABA as monotherapy. Indeed, LAMA and LABA bronchodilator monotherapy currently provide the mainstay for treatment-naïve, moderately symptomatic patients with little/ no exacerbation history; these therapies are These studies were not performed using inclusion criteria to specifically only include patients with COPD with an exacerbation history in the previous year; this gap in knowledge has been filled by the FLAME study, showing that LAMA/LABA had a greater impact in exacerbation prevention than ICS/ LABA in this specific COPD subgroup [71] . There is evidence to suggest that patients with an elevated blood eosinophil count may achieve particular benefit from ICS therapy in terms of reducing exacerbations; however, an appropriate eosinophil count threshold to identify such a patient subgroup has yet to be established [73] . Further investigations into patient grouping, identifying patients with COPD who will respond more favorably to certain treatments, and measurable biomarkers are ongoing. For example, a 12-week, randomized, open-label, parallel-group study (NCT02546349) of LABA/ICS versus LAMA stratified by high and low exhaled nitric oxide levels (C23.5 vs. \23.5 ppb), which is a surrogate marker for eosinophilic airway inflammation, is underway and findings are keenly anticipated [74] .
It has been proposed that LAMA/LABA dual bronchodilation is an appropriate intervention in patients with persistent breathlessness and exercise impairment that remain troublesome despite LAMA monotherapy [73] ; however, no 
